AU2012289964B2 - Trans-clomiphene metabolites and uses thereof - Google Patents

Trans-clomiphene metabolites and uses thereof Download PDF

Info

Publication number
AU2012289964B2
AU2012289964B2 AU2012289964A AU2012289964A AU2012289964B2 AU 2012289964 B2 AU2012289964 B2 AU 2012289964B2 AU 2012289964 A AU2012289964 A AU 2012289964A AU 2012289964 A AU2012289964 A AU 2012289964A AU 2012289964 B2 AU2012289964 B2 AU 2012289964B2
Authority
AU
Australia
Prior art keywords
clomiphene
trans
metabolite
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012289964A
Other languages
English (en)
Other versions
AU2012289964A1 (en
Inventor
Joseph S. Podolski
Ronald D. Wiehle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repros Therapeutics Inc
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46724628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012289964(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of AU2012289964A1 publication Critical patent/AU2012289964A1/en
Application granted granted Critical
Publication of AU2012289964B2 publication Critical patent/AU2012289964B2/en
Priority to AU2017204171A priority Critical patent/AU2017204171A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2012289964A 2011-08-04 2012-08-03 Trans-clomiphene metabolites and uses thereof Ceased AU2012289964B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017204171A AU2017204171A1 (en) 2011-08-04 2017-06-20 Trans-Clomiphene Metabolites And Uses Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161515278P 2011-08-04 2011-08-04
US61/515,278 2011-08-04
PCT/US2012/049451 WO2013020017A1 (en) 2011-08-04 2012-08-03 Trans-clomiphene metabolites and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017204171A Division AU2017204171A1 (en) 2011-08-04 2017-06-20 Trans-Clomiphene Metabolites And Uses Thereof

Publications (2)

Publication Number Publication Date
AU2012289964A1 AU2012289964A1 (en) 2014-01-30
AU2012289964B2 true AU2012289964B2 (en) 2017-03-23

Family

ID=46724628

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012289964A Ceased AU2012289964B2 (en) 2011-08-04 2012-08-03 Trans-clomiphene metabolites and uses thereof
AU2017204171A Abandoned AU2017204171A1 (en) 2011-08-04 2017-06-20 Trans-Clomiphene Metabolites And Uses Thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017204171A Abandoned AU2017204171A1 (en) 2011-08-04 2017-06-20 Trans-Clomiphene Metabolites And Uses Thereof

Country Status (21)

Country Link
US (1) US9981906B2 (https=)
EP (2) EP3351527A1 (https=)
JP (2) JP6433785B2 (https=)
KR (1) KR20140054110A (https=)
CN (1) CN103702975B (https=)
AU (2) AU2012289964B2 (https=)
BR (1) BR112014000908A2 (https=)
CA (1) CA2841572C (https=)
CL (1) CL2014000268A1 (https=)
CO (1) CO6862154A2 (https=)
CR (1) CR20140124A (https=)
EA (1) EA201490416A1 (https=)
IL (1) IL230287B (https=)
MX (1) MX355316B (https=)
MY (2) MY191802A (https=)
NI (1) NI201400008A (https=)
PH (1) PH12014500144A1 (https=)
SG (1) SG10201606425WA (https=)
UA (1) UA113291C2 (https=)
WO (1) WO2013020017A1 (https=)
ZA (1) ZA201400406B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120284764A1 (en) * 2011-05-05 2012-11-08 Keith Ball Method and system for requesting services by a media device
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
SG11201407397WA (en) 2012-05-31 2014-12-30 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
ES2688821T3 (es) 2012-11-02 2018-11-07 Repros Therapeutics Inc. Métodos y composiciones para tratar afecciones dependientes de la progesterona
WO2014070523A1 (en) * 2012-11-02 2014-05-08 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
WO2017123577A1 (en) * 2016-01-12 2017-07-20 Repros Therapeutics Inc. Trans-clomiphene and progesterone receptor antagonist combination therapy for treating hormone-dependent conditions
CN108883083A (zh) * 2016-02-25 2018-11-23 艾森潘帕克制药股份有限公司 两种氯米芬异构体的口服剂型及使用其治疗继发性腺功能减退症的方法
WO2017182097A1 (en) 2016-04-22 2017-10-26 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Process for the preparation of enclomiphene citrate having needle shaped crystal habit.

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
US4061733A (en) 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3660489D1 (en) 1985-06-08 1988-09-15 Asta Pharma Ag Derivatives of 1,1,2,2-tetramethyl-1,2-bis(2-fluoro-4-hydroxyphenyl) ethane
US4820736A (en) * 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8926171D0 (en) 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
KR100326962B1 (ko) 1992-09-15 2002-12-02 메렐 파마슈티칼스 인크. 타목시펜-내성종양치료용비대사성클로미펜유사체
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
AU2638795A (en) 1994-06-17 1996-01-15 University Of Nebraska Board Of Regents In situ gel-forming delivery vehicle for bio-affecting substances, and method of use
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
AU6824996A (en) 1995-08-17 1997-03-12 Dyer, Alison Margaret Controlled release products
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
JP2002511777A (ja) 1996-10-28 2002-04-16 ゼネラル ミルズ，インコーポレイテッド 調放性粒子の埋包およびカプセル化
ATE279461T1 (de) 1997-04-03 2004-10-15 Guilford Pharm Inc Bioabbaubare terephthalat polyester-polyphosphat polymere, zusammensetzungen, gegenstände und verfahren für ihre herstellung und verwendung
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040186185A1 (en) 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
MXPA01000794A (es) 1998-07-30 2002-04-08 Stoller Ets Tratamiento de plantas con acido salicilico y aminas organicas.
WO2000007996A2 (en) 1998-08-07 2000-02-17 Chiron Corporation Pyrazoles as estrogen receptor modulators
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TR200200406T2 (tr) 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
CA2321321A1 (en) 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
WO2001052823A2 (en) 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
CN1400904A (zh) 2000-01-28 2003-03-05 恩多研究公司 与雌激素联合的选择性雌激素受体调节剂
US7067557B2 (en) 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
JP2003534375A (ja) 2000-05-26 2003-11-18 フィッチ，ハリー 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法
JP2004507465A (ja) 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2002030355A2 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
US6743448B2 (en) 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
PL211339B1 (pl) 2001-07-09 2012-05-31 Zonagen Zastosowanie kompozycji do wytwarzania leku do leczenia niedoboru testosteronu u samców ssaków
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
CA2459943A1 (en) 2001-09-21 2003-04-03 Merck & Co., Inc. Androstanes as androgen receptor modulators
US20060269611A1 (en) 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
WO2006019916A1 (en) 2004-07-14 2006-02-23 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
CN101115709B (zh) * 2004-12-13 2011-04-13 小野药品工业株式会社 氨基羧酸衍生物及其医药用途
CA2595363C (en) 2005-02-04 2012-03-27 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
AU2006213856B2 (en) 2005-02-11 2011-03-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent
EP1865938A4 (en) * 2005-03-22 2008-09-24 Repros Therapeutics Inc DOSAGE SCHEMES FOR TRANS-CLOMIPHENE
EP1896134A2 (en) 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
BRPI0615165A2 (pt) * 2005-08-05 2016-09-13 Repros Therapeutics Inc método de tratamento de infertilidade
US7613937B2 (en) 2005-10-31 2009-11-03 Hewlett-Packard Development Company, L.P. Method and apparatus for utilizing a microcontroller to provide an automatic order and timing power and reset sequencer
JP2009527504A (ja) 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
US20080112888A1 (en) 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
CN101766000A (zh) 2007-06-26 2010-06-30 传媒专利有限公司 管理组播组的方法和设备
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
SG185311A1 (en) * 2007-10-16 2012-11-29 Repros Therapeutics Inc Trans-clomiphene for metabolic syndrome
US20100111901A1 (en) 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
TWI458478B (zh) 2008-11-07 2014-11-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
CA2881604C (en) 2011-08-09 2021-09-14 Kenneth W. Adams Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
JP2015508825A (ja) 2012-02-29 2015-03-23 レプロス セラピューティクス インコーポレイティド アンドロゲン欠乏症を治療するための併用療法
BR112015002288A2 (pt) 2012-08-21 2017-07-04 Repros Therapeutics Inc formulações de trans-clomifeno e usos das mesmas
CN103351304B (zh) 2013-07-01 2015-12-09 暨明医药科技（苏州）有限公司 一种克罗米芬的合成方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAUMANN, R. J. ET. AL. Biochemical Pharmacology, 1998, 55, 841-851 *
BOIAN, G. ET. AL. Analytical & Bioanalytical Chemistry, 2011, 400, 3429-3441 *
RUENITZ, P. C. ET. AL. Cancer Research, 1987, 47, 4015-4019 *
RUENITZ, P. C. ET. AL. Journal of Medicinal Chemistry, 1989, 32, 192-197 *

Also Published As

Publication number Publication date
US20140163114A1 (en) 2014-06-12
EP2744777A1 (en) 2014-06-25
CN103702975A (zh) 2014-04-02
NI201400008A (es) 2015-12-10
US9981906B2 (en) 2018-05-29
EA201490416A1 (ru) 2014-11-28
AU2012289964A1 (en) 2014-01-30
UA113291C2 (xx) 2017-01-10
KR20140054110A (ko) 2014-05-08
PH12014500144A1 (en) 2014-02-24
CL2014000268A1 (es) 2014-11-14
HK1196349A1 (zh) 2014-12-12
JP2014529584A (ja) 2014-11-13
SG10201606425WA (en) 2016-09-29
JP2019023210A (ja) 2019-02-14
IL230287B (en) 2019-07-31
NZ621892A (en) 2016-03-31
EP3351527A1 (en) 2018-07-25
BR112014000908A2 (pt) 2017-02-21
CO6862154A2 (es) 2014-02-10
CA2841572A1 (en) 2013-02-07
MX355316B (es) 2018-04-16
CN103702975B (zh) 2016-03-16
WO2013020017A1 (en) 2013-02-07
JP6433785B2 (ja) 2018-12-05
CA2841572C (en) 2020-10-13
MY191802A (en) 2022-07-15
ZA201400406B (en) 2014-11-26
MX2014000825A (es) 2014-02-27
AU2017204171A1 (en) 2017-07-13
IL230287A0 (en) 2014-03-06
CR20140124A (es) 2014-05-13
MY170718A (en) 2019-08-27

Similar Documents

Publication Publication Date Title
AU2012289964B2 (en) Trans-clomiphene metabolites and uses thereof
Y. Maximov et al. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice
TW200410711A (en) Prevention and treatment of androgen-deprivation induced osteoporosis
JP2023525571A (ja) 肝障害の併用処置
JP2021046448A (ja) 癌療法における使用のためのトランス−クロミフェン
US20160038506A1 (en) Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
TWI458478B (zh) 用於代謝症候群與第２型糖尿病的反式氯米芬
CN1988909A (zh) 包含5－α还原酶抑制剂和SERM的组合物及其使用方法
NZ621892B2 (en) Trans-clomiphene metabolites and uses thereof
HK1196349B (zh) 反式-氯米芬代謝物及其用途
EP3300725A2 (en) Selective estrogen receptor modulators with short half-lives and uses thereof
JP2008511615A (ja) アンドロゲン欠乏症の治療法または予防法に使用する医薬調製物の製造に用いるエストロゲン受容体選択的調節物質
KR20230060465A (ko) 장내 glp-1 분비 촉진 및 염증 완화 효능을 가지는 아젤라산 조성물
HK1240110A1 (en) Selective estrogen receptor modulators with short half-lives and uses thereof
KR20180112048A (ko) 클로미펜 이성질체들의 경구 제형 및 이차 생식선 기능저하증 치료를 위하여 이들을 사용하는 방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired